Viatris VTRS Brands — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viatris in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viatris's brands — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viatris's brands — net sales?
- Viatris (VTRS) reported brands — net sales of $2.33B in Q1 2026.
- How has Viatris's brands — net sales changed year-over-year?
- Viatris's brands — net sales increased by 10.2% year-over-year, from $2.12B to $2.33B.
- What is the long-term trend for Viatris's brands — net sales?
- Over 4 years (2021 to 2025), Viatris's brands — net sales has grown at a -4.1% compound annual growth rate (CAGR), from $10.84B to $9.18B.
- What does brands — net sales mean?
- This metric represents the total revenue generated from the sale of branded pharmaceutical products within the company's portfolio. It reflects the market demand and pricing power of established, often off-patent, drug assets that serve as a core revenue pillar. This figure is critical for assessing the stability and cash flow generation of the company's legacy product base.